Merck & Co Inc (MRK)
127.51
-0.75
(-0.58%)
USD |
NYSE |
May 03, 16:00
127.59
+0.08
(+0.06%)
After-Hours: 20:00
Merck Research and Development Expense (Annual): 30.53B for Dec. 31, 2023
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 30.53B |
| December 31, 2022 | 13.55B |
| December 31, 2021 | 12.24B |
| December 31, 2020 | 13.40B |
| December 31, 2019 | 9.724B |
| December 31, 2018 | 9.752B |
| December 31, 2017 | 10.34B |
| December 31, 2016 | 10.26B |
| December 31, 2015 | 6.704B |
| December 31, 2014 | 7.18B |
| December 31, 2013 | 7.503B |
| December 31, 2012 | 8.168B |
| December 31, 2011 | 8.467B |
| December 31, 2010 | 11.11B |
| December 31, 2009 | 5.845B |
| December 31, 2008 | 4.805B |
| Date | Value |
|---|---|
| December 31, 2007 | 4.883B |
| December 31, 2006 | 4.783B |
| December 31, 2005 | 3.848B |
| December 31, 2004 | 4.010B |
| December 31, 2003 | 3.280B |
| December 31, 2002 | 2.677B |
| December 31, 2001 | 2.456B |
| December 31, 2000 | 2.344B |
| December 31, 1999 | 2.068B |
| December 31, 1998 | 1.821B |
| December 31, 1997 | 1.684B |
| December 31, 1996 | 1.487B |
| December 31, 1995 | 1.331B |
| December 31, 1994 | 1.231B |
| December 31, 1993 | 1.173B |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
9.724B
Minimum
2019
30.53B
Maximum
2023
15.89B
Average
13.40B
Median
2020
Research and Development Expense (Annual) Benchmarks
| Amgen Inc | 4.784B |
| Johnson & Johnson | 15.08B |
| Eli Lilly and Co | 9.313B |
| Pfizer Inc | 10.68B |
| Moderna Inc | 4.845B |